Amarin Corp Plc (AMRN)

[VuBru]

Kiwi - Good point. The company has said this and I believe the extra patient contacts are important for study retention and compliance. I was in a meeting last week where several FDA officials were present, and a high level person at one point commented on how hard it is to keep patients actively engaged in a "long-term study," and this was referring to months not years. CV trials may be a different animal though - all of the MACE outcome trials are very long, and maybe CAD (and high risk diabetic) patients have more reason to stay in a trial as the outcomes are literally life and death.